CD8A and autoimmune disease: Arguably the strongest evidence that checkpoint blockade globally disrupts peripheral tolerance is that the primary side-effects of therapy are inflammatory and autoimmune symptoms, including organ-specific CD8+ T cell mediated autoimmune diseases such as Vitiligo and Type I Diabetes (200).